Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Clin Pract
Autori principali: Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G
Natura: Artigo
Lingua:Inglês
Pubblicazione: BlackWell Publishing Ltd 2013
Soggetti:
Endocrinology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282288/
https://ncbi.nlm.nih.gov/pubmed/24118688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12322
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi